We have developed polyelectrolyte gene delivery vectors that display good extracellular stability and are activated intracellularly to permit transgene expression. The strategy comprises covalent crosslinking of primary amines in poly-L-lysine/DNA complexes with a crosslinking agent that can later be cleaved by reduction. Crosslinked complexes maintained the same size and surface charge but showed increased stability against polyelectrolyte exchange with poly-L-aspartic acid. Surface modification with polyethyleneglycol improved solubility and masked their positive surface charge. Crosslinked complexes showed 10-fold increased plasma circulation following intravenous administration to Balb/c mice. In the absence of chloroquine, the levels of transgene expression in B16F10 murine melanoma cells were similar for crosslinked and non-crosslinked complexes, however, chloroquine selectively potentiated trans-
Introduction
Attempts to develop effective alternatives to viral vectors for gene delivery are continually frustrated by difficulties of combining extracellular stability of the new vector with ready availability of the DNA following entry into the target cell. Extracellular stability is essential to enable development of robust delivery systems capable of withstanding the aggressive biological environment en route to the target site, while availability of the DNA for transcription is fundamental to permitting efficient expression of therapeutic transgenes within target cells.
We are addressing this challenge by seeking to identify endogenous trigger mechanisms that enable polycation/ DNA vectors (polyplexes), stabilized during the delivery phase, to be activated at the target site to present the DNA for efficient transcription. Since many sophisticated gene delivery systems recognize specific receptors on the target cell membrane, trigger mechanisms can be based on pathways of downstream processing that follow initial binding of the vector to the cell surface. These can include designing the vectors for activation by a low pH-cata-gene expression by the non-crosslinked complexes. Cellular uptake of the complexes was the same, irrespective of crosslinking. Following microinjection into the cytoplasm of Xenopus oocytes, or the cytoplasm or nucleus of Rat-1 fibroblasts, crosslinked complexes mediated the same transgene expression as non-crosslinked complexes, indicating crosslinked complexes are rapidly reduced and activated intracellularly. We therefore hypothesize that the lower in vitro transfection activity of crosslinked complexes in the presence of chloroquine is due to reduced transfer from endosome to cytoplasm, mainly due to increased stability against destabilization by chloroquine. The extended systemic circulation together with triggered intracellular activation makes these complexes a promising system for targeted gene delivery in vivo. Gene Therapy (2001) 8, 713-724. lyzed hydrolysis in the endosome/lysosome of target cells, for enzymatic cleavage within these compartments, for example, by lysosomal proteases, or for cleavage by the increased reducing environment inside the cell.
Several means have previously been addressed for stabilization of polycation/DNA vectors that are compatible with triggered activation at the target site. These include modification of the surface of the vector with reactive polymers that introduce a stealth-like coating, protecting the vector from binding to proteins and cells and endowing it with 'steric stabilization'. 1, 2 The coating polymers can be designed for controlled degradation within cells in order to achieve destabilization of the vector, making the DNA available for transcription, following exposure to the appropriate trigger mechanism. However, it is increasingly apparent that the presence of a simple layer of coating polymer on the surface of the vector does not endow them with complete stability against biological challenge, possibly because proteins and polyanions can slowly penetrate through the polymer layer and destabilize the core of the vector, or possibly because the attachment of the hydrophilic polymer can destabilize the binding of individual polycations to DNA (see later).
This situation may be solved by the use of multivalent coating polymers, designed to form multiple bonds with the surface of the vector, crosslinking it and providing 'lateral stabilization' as well as a surface polymer layer. 2 
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These agents can give complete protection against disruption by proteins and polyanions, although initial attempts to combine them with endogenous trigger mechanisms, releasing the DNA for transcription, have so far met with only limited success. However, despite the elegance of this approach, it may not be necessary to combine the requirement for steric and lateral stabilization into a single chemical step. Indeed, a simpler concept is to use a low molecular weight crosslinking agent to provide lateral stabilization, with monovalent polymer being used to provide the polymer coating. In this way it should be possible to produce a stabilized vector with extended systemic circulation that is activated following appropriate processing at the target site. To our knowledge, nobody has previously examined this possibility.
In this study we have used a low molecular weight bifunctional disulfide-containing crosslinking agent to stabilize poly(l-lysine) (PLL)/DNA complexes. Subsequent reduction of the disulfide bonds (eg in the cytoplasm or nucleus of target cells) removes the crosslinks and reverses the stabilization ( Figure 1 ). However, despite their stability, these crosslinked complexes are highly charged and bind to cells and proteins, and therefore we have introduced a surface coating of poly(ethylene glycol) (PEG) to provide steric stabilization and improve solubility. Together these modifications are shown to lead to extended circulation properties of the complexes following intravenous administration to mice, coupled with reductive activation that leads to efficient transgene expression following entry into the cytoplasm of target cells.
Results
Choice of crosslinking agent Our first objective in this study was to demonstrate that PLL/DNA complexes could be covalently crosslinked with low molecular weight agents, resulting in stabilization against disruption by biological molecules. The presence of primary amino groups within PLL enables the choice of several types of crosslinkers. From a range of commercially available materials, we have tested several imidoester and succinimidyl active ester crosslinkers containing reducible disulfide bonds. Although several of these agents were able to stabilize the complexes, in the assays described below, the use of imidoester-type crosslinkers (eg DTBP (dimethyl-3,3′-dithiobispropionimidate)) has proved advantageous because of their ability to preserve the original size of PLL/DNA complexes, determined by photon correlation spectroscopy (PCS). In contrast, the use of other types of crosslinkers (eg 3,3′-dithiobis(sulfosuccinimidyl propionate), DTSSP) induced significant increases in the size of complexes. Since the imidoesters preserve the positive charge following reaction with amino groups (Figure 1 ), they preserve also the overall positive charge of the complexes, which is known to play an important role in their colloidal stability.
A simple means to measure stabilization of complexes is to evaluate their susceptibility to disruption by polyanions, determining the release of free DNA by electrophoresis. Using this approach we found the complexes could be stabilized against polyelectrolyte exchange reactions with poly-l-aspartic acid (PAA). A high concen- 
a). The lateral stabilization induced by crosslinking provides extracellular stability leading to the extended circulation times of the complexes (coated with PEG) after intravenous administration to mice (b). Efficient intracellular reductive activation of the complexes following entry into the cytoplasm of target cells allows subsequent transgene expression (c).
tration of PAA was used to challenge the complexes (1 mg/ml), some 20-fold higher than the concentration necessary to release DNA quantitatively from noncrosslinked complexes (40-60 g/ml), permitting detection of highly stabilized complexes. We evaluated the effects of treating complexes with DTBP at 0, 0.1, 0.25, 0.5, 1.0, 2.5 and 10-fold molar excess (ie molar excess with respect to total amino groups in PLL) and found that subsequent challenge with 1 mg PAA/ml could release most of the DNA from the complexes treated with lower amounts of DTBP (Figure 2A ). However, DTBP(1) complexes (ie complexes treated with one mole DTBP per mole PLL amino groups) and above showed significant retention of DNA in the well, indicating it could not be Gene Therapy fully displaced from the complex by PAA. When complexes were treated with DTBP(2.5) and higher, they were completely stable to challenge by PAA and no free DNA could be discerned on the gel (Figure 2A ). Treating complexes with less than DTBP(1) did show some retention of DNA in the well, suggesting limited stabilization, and this was confirmed using lower concentrations of PAA (data not shown). The possibility to reverse the DTBP crosslinking was demonstrated by treating the complexes with DTT, reducing the disulfide bond within the DTBP crosslinks and leading to release of free DNA following subsequent challenge with PAA ( Figure 2B ).
An alternative method to monitor stability of crosslinked complexes to PAA challenge involves measuring the restoration of ethidium bromide fluorescence. Addition of PAA to non-crosslinked complexes in the presence of ethidium bromide led to a substantial increase in the fluorescence of ethidium bromide, whereas the increase observed for DTBP(10) complexes was significantly lower ( Figure 2C ). This suggests that the presence of crosslinks inhibits the ability of PAA to bind PLL in the complex and regenerate ethidium bromide binding sites in the DNA. Reduction of the disulfide bonds in the crosslinked complexes with 25 mm DTT led to full restoration of fluorescence, again indicating the simple reversibility of crosslinking by reduction.
Crosslinking increases stability of complexes against dissociation with NaCl The formation of DNA complexes is a simple exchange reaction during which the sodium counter ions associated with DNA are exchanged for polycation molecules, releasing low molecular weight salt. Due to the co-operative nature of polycation binding, the newly formed interactions are stronger than the original ones and the reaction equilibrium is shifted almost completely in the direction of complexes. The thermodynamic driving force for such binding is the release of the low molecular weight counter ions associated with the polyelectrolytes into the external media, which is accompanied by a substantial entropy gain. 3 Increasing the concentration of salt sufficiently high can shift the reaction equilibrium back towards the starting materials, ie DNA and PLL. A convenient means to measure complex formation or dissociation in the presence of high salt concentrations is to measure the intensity of scattered light, known to be proportional to molecular weight, concentration and shape of the scattering particles. Light scattering is dramatically increased when complexes are formed, particularly in the aggregated state as found in salt solutions, compared to a mixture of DNA and polycation. Figure 3 shows intensity of light scattered by the solutions of complexes in the presence of increasing concentration of NaCl. Using non-crosslinked complexes the scattering intensity decreases suddenly at NaCl concentrations around 1.1 m suggesting dissociation of the complexes to free DNA and polycation. Dissociation of the complexes at this concentration of NaCl was confirmed using FITC-PLL/DNA complexes using a filtration-based assay similar to that described by Erbacher et al 4 (data not shown). Reaction with DTBP crosslinker at low concentrations (molar ratio 0.5-1) caused a shift of the point of dissociation to higher NaCl concentrations, probably because the partial crosslinking causes an effective increase in the molecular weight of the PLL within the complex, which consequently increases the strength of its interaction with DNA. At higher concentrations of DTBP (molar ratio 2.5 and above) the scattering intensity remains elevated even at very high concentrations of salt, probably because under these conditions PLL on the surface of the complex becomes crosslinked to form a continuous surface network. DNA cannot dissociate from these complexes even at very high salt concentrations and remains trapped inside. We propose that this may be considered as a 'gelation' of the complexes, leading to formation of 'nanogel' particles. Again the stabilization by crosslinking was shown to be completely reversible following reduction of disulfide crosslinks of DTBP (10) complexes with 25 mm DTT, restoring the original profile for dissociation of the complexes in salt (Figure 3 ).
Effect of crosslinking on size, -potential, and aggregation of PLL/DNA vectors The size of polycation/DNA complexes is an important parameter determining their biological activity both in vitro and in vivo. 1, 5 In this study we have treated the complexes with a bifunctional crosslinking agent, and therefore it is possible that PLL in separate complexes could become crosslinked, leading to undesired aggregation of the particles. However, as data in Table 1 show, the sizes of the complexes crosslinked with increasing concentrations of DTBP did not change compared with noncrosslinked complexes. This suggests that the concentration of complexes in the reaction mixture is too low to permit significant inter-particle crosslinking. Analysis of the morphology of complexes using transmission electron microscopy (TEM) showed no difference following crosslinking of complexes ( Figure 4A and B); in both cases (DTBP(0) and DTBP(10)) the complexes appeared as discrete particles (with small portion of rods) with sizes in the range 40-80 nm. Furthermore, measuring surface charge ( potential) of the complexes revealed no significant change in their overall positive charge following DTBP treatment (Table 1) .
The tendency of PLL/DNA complexes to aggregate in % of amino groups reacted with PEG in coating reaction as determined by TNBSA assay.
Figure 4 Transmission electron microscopy of DNA complexes. Electron micrographs of non-crosslinked DTBP(0) (A), crosslinked DTBP(10) (B), non-crosslinked PEG-DTBP(0) (C), and crosslinked PEG-DTBP(10) (D) complexes at 50 000 magnification are shown (bar indicates 100 nm). PEG-DTBP(0) and PEG-DTBP(10) were coated at PEG-NHS concentration of 3 mg/ml.
physiological saline solution represents a significant drawback in their handling and potential practical use as gene delivery vectors. Recently, it was reported that crosslinked PLL/DNA complexes were less prone to saltinduced aggregation. 6 We therefore examined aggregation of PLL/DNA complexes in 0.15 m NaCl, but no significant effect of crosslinking was observed and both the crosslinked and non-crosslinked complexes aggre-gated extensively over 30 min, reaching sizes of ෂ1 m (data not shown). Fortunately, methods are available to increase the solubility of such PLL/DNA complexes, including surface modification of the complexes with PEG or other hydrophilic polymers.
1,2,7 Using PEG-Nhydroxysuccinimidyl ester (PEG-NHS) we were able to stabilize the crosslinked complexes against salt-induced aggregation by covalent surface modification, providing steric stabilization and increasing their solubility. The same approach was also effective for non-crosslinked complexes ( Table 1) . Analysis of residual amino groups using the TNBSA assay showed that 30-50% of available PLL amino groups reacted in the coating reaction (compared with matched non-PEG-coated controls) and PCS measurements showed that the coating increased diameters of the complexes by about 20 nm (Table 1) .
Surface modification of the PLL/DNA complexes with PEG-NHS not only decreased their tendency to aggregate, but also screened their positive surface charge (Table 1) . Analysis of their morphology by TEM showed again discrete structures ( Figure 4C and D), although especially the images of PEG-DTBP(10) repeatedly revealed significantly clearer pictures of the rod and toroid morphologies than non-crosslinked analogue PEG-DTBP(0). Similar morphologies have been observed previously for PEG-containing polyelectrolyte complexes. 8 Influence of PEG-coating on the stability of PLL/DNA complexes Surface modification of crosslinked and non-crosslinked complexes with PEG-NHS improved solubility and decreased salt-induced aggregation in both cases. However, coating with PEG-NHS had a destabilizing effect on complexes that were not crosslinked. For example, we examined the susceptibility of complexes to dissociation in NaCl solutions, measured using a light scattering assay ( Figure 5 ). Whereas non-coated complexes were stable in NaCl solutions up to 1 m, showing dissociation at approximately 1.1 m, the presence of a PEG coating (introduced using 1.5 mg PEG-NHS/ml) actually destabilized the complex and caused dissociation at lower salt concentrations. Further increasing the concentration of Figure 5 Destabilizing effect of PEG coating on stability of DNA complexes against dissociation with NaCl. Effect of crosslinking on the stability of the non-crosslinked complexes coated with 0 mg/ml (᭺), 1.5 mg/ml (᭝), and 3 mg/ml (×) of PEG-NHS against NaCl dissociation was studied using a fluorimeter with exc = em = 600 nm. To 2 ml of complexes in Hepes pH 7.8 aliquots of 5 m NaCl were added and changes in the intensity of scattered light were followed.
Gene Therapy PEG-NHS used in the coating reaction led to a further fall in the concentration of NaCl necessary to dissociate the complexes.
We also evaluated whether stability to challenge by PAA was decreased by PEG-coating of non-crosslinked PLL/DNA complexes, using agarose gel electrophoresis to determine the release of free DNA. Whereas the onset of the release of free DNA from non-coated complexes required challenge with PAA at concentrations of 10-15 g PAA/ml, concentrations as low as 5 g/ml were sufficient to start to release DNA from PEG-coated complexes, confirming the decreased thermodynamic stability of PEG-coated complexes (data not shown).
Interaction of crosslinked and non-crosslinked PLL/DNA complexes with cationic molecules Addition of free PLL to PEG-coated complexes in the presence of 0.15 m NaCl caused aggregation of noncrosslinked PEG-coated complexes ( Table 2 ). The 98% increase in diameter (from 85 to 168 nm) of noncrosslinked PEG-coated complexes represents almost eight-fold increase in their volume, and aggregation was even greater when more PLL was added (data not shown). This increase in diameter caused by PLL was inhibited by DTBP crosslinking, with PEG-DTBP (10) complexes showing only 5% size increase under the same conditions ( Table 2) .
The most likely explanation for the aggregation of noncrosslinked complexes is an exchange reaction of the free PLL added with PLL-PEG conjugates on the surface of the PEG-coated PLL/DNA complexes. As a result, the complexes lose their protective PEG layer and thus become more prone to aggregation. The fact that the complexes do not precipitate entirely after addition of PLL suggests that PLL replaces only part of PEG-PLL establishing a new equilibrium between the complexes and PLL.
We also studied the interaction of PLL/DNA complexes with another cationic molecule -chloroquine, which is known to bind DNA via both its quinoleic moiety and positive charges. Treatment with 1 mm chloroquine caused significant aggregation of PLL/DNA complexes, while the size of the corresponding crosslinked complexes (DTBP(10)) remained almost unchanged (Table 2) . PEG-coated complexes all showed less susceptibility to aggregation in 1 mm chloroquine. The endosomal/lysosomal concentration of chloroquine is estimated to reach levels as high as 20 mm, 4 and under these conditions both non-crosslinked and DTBP(10) noncoated complexes showed rapid aggregation, although the PEG-coated DTBP(10) showed less aggregation than the PEG-coated non-crosslinked complex (Table 2 ). These data suggest that chloroquine can disturb the structure of non-crosslinked complexes more easily than crosslinked ones, leading to increased interaction with other complexes. In a biological system, the chloroquine might selectively increase binding of the non-crosslinked complexes to cells and membranes, for example the endosome membrane.
Crosslinking of PEG-coated complexes increases circulation times in mice In order to determine whether the increased stability of DTBP-crosslinked complexes was reflected in improved biodistribution in vivo, crosslinked and non-crosslinked PLL/DNA complexes were coated with PEG (to improve solubility and decrease protein binding) and injected into the tail vein of female Balb/c mice. Non-crosslinked complexes showed rapid clearance from the blood circulation, while crosslinked complexes showed significantly increased blood concentration 30 min after injection (Figure 6a) , with circulation times increasing in parallel with the degree of crosslinking. Forty percent of complexes crosslinked with DTBP(10) were found in the bloodstream, compared with 26% for DTBP(2.5) and 6% for non-crosslinked complexes. Uptake into the liver showed exactly the reverse trend. The ratio between the amount of complexes found in the liver and in the blood (liver/blood index) was decreased from 12 for PEGcoated non-crosslinked complexes to 2 for PEG-DTBP(2.5) and 1.1 for PEG-DTBP(10), suggesting decreased recognition of the complexes by liver phagocytic cells (Figure 6a ). Crosslinked complexes remaining in the blood were found predominantly (Ͼ90%) in the plasma.
Decreasing the concentration of PEG-NHS during the coating reaction from 3 to 0.75 mg/ml leads to a substantial decrease in the blood circulation of the crosslinked complexes ( Figure 6b ) and also to an increase in lung deposition of the complexes (insert in Figure 6b ). In contrast, decreasing the amount of PEG-NHS used for the coating of non-crosslinked complexes does not affect their circulation times.
Effect of crosslinking of PLL/DNA complexes on gene expression in vitro
It is important that the increased stability leading to prolonged circulation of crosslinked complexes should not also prevent transgene expression within target tissues. Therefore we examined the consequences of crosslinking complexes on their ability to transfect cells in vitro.
Crosslinking conditions up to DTBP(1) did not significantly change the transfection efficiency in B16F10 cells in the presence of chloroquine, however, DTBP(2.5) displayed almost 20-fold decreased transfection, and almost 100-fold decrease was observed for DTBP (10) (Figure 7) . Concentrations of DTBP above DTBP(10) resulted in a total suppression of transgene expression. A similar trend was observed for crosslinked complexes coated with PEG-NHS (data not shown).
Methanol is released as a by-product during the reaction of DTBP with PLL amino groups, and also some of the DTBP is hydrolysed to produce ammonium chloride and 3,3′-dithiobis(dimethylpropionate). The possibility that these by-products can affect the transfection was tested by including them at appropriate concentrations in transfection experiments using non-crosslinked complexes. None of the compounds showed any significant effect on the transfection efficiency (data not shown), indicating that the decrease in transfection of crosslinked complexes is due to their modified properties introduced by crosslinking.
To determine which step or steps of the intracellular gene delivery process accounts for the decreased transgene expression, we first quantified the uptake of radiolabeled complexes into B16F10 cells in vitro. We evaluated the uptake of non-crosslinked complexes (DTBP(0)), and also the crosslinked complexes that showed the best circulation times in vivo (DTBP(10)), with and without PEG coating. Complexes coated with PEG showed much less uptake than non-coated complexes, although within each type there was little difference between crosslinked and non-crosslinked complexes (Figure 8 ). The reduced uptake of PEG-coated complexes is in accordance with neutral surface charge of these complexes (Table 1) , which decreases nonspecific uptake caused by surface binding and adsorptive endocytosis. Since the cellular uptake of the complexes was not affected by crosslinking, we considered that the decreased transgene expression of crosslinked complexes might result from inadequate intracellular reducing activity, preventing full reduction of the complexes and activation of the DNA. This was evaluated directly, by microinjecting the complexes into the cytoplasm and nucleus of Xenopus oocytes and Rat-1 fibroblasts, and measuring resultant transgene expression. Following intracytoplasmic microinjection into Xenopus oocytes the luciferase transgene expression provided by highly crosslinked DTBP(10) was the same 
P-labeled complexes were incubated with the cells for 4 h in DMEM containing 100 m chloroquine and 10% FCS. The incubation was performed at 37 and 4°C. The uptake of noncrosslinked DTBP(0), crosslinked DTBP(10), non-crosslinked PEG-DTBP(0), and crosslinked PEG-DTBP(10) complexes is represented as a percentage of the total after correction for cell binding determined at 4°C. PEG-DTBP(0) and PEG-DTBP(10) were coated at PEG-NHS concentration of 3 mg/ml. The results are presented as a mean and standard deviation obtained from three samples.
Gene Therapy as that observed for non-crosslinked complexes (DTBP(0)). Similarly, PEG-coated non-crosslinked (PEG-DTBP(0)) and crosslinked (PEG-DTBP (10)) complexes all showed the same activity (Figure 9a) . Interestingly, PEGcoating appeared to increase the gene expression with both the crosslinked and non-crosslinked complexes.
Although Xenopus oocytes provide useful information they differ distinctly from mammalian cells and it was considered important to determine the activity of complexes following microinjection into mammalian cells. We have therefore studied the transgene expression of the crosslinked and non-crosslinked complexes following their microinjection into cytoplasm and nucleus of Rat-1 fibroblasts. The experiments were performed using a plasmid containing GFP gene and results were quantified as the percent of cells injected that are found by microscopy to express a significant fluorescence signal. Mean values of the percentage of expressing cells obtained following both cytoplasmic and nuclear injections are shown in Figure 9b . Similarly to Xenopus
Figure 9 Microinjection of DNA complexes into cytoplasm of Xenopus oocytes and into cytoplasm and nucleus of RAT-1 fibroblasts. (a) The Xenopus oocytes were injected into cytoplasm with pGL3-control plasmid containing complexes within 48 h after isolation. Forty-eight hours later they were assessed for luciferase gene expression. Gene expression of noncrosslinked DTBP(0), crosslinked DTBP(10), non-crosslinked PEG-DTBP(0), and crosslinked PEG-DTBP(10) complexes is reported as the mean RLU per five oocytes (randomly chosen) and standard deviation obtained from at least 12 groups of five oocytes. (b) Rat-1 fibroblasts were injected into cytoplasm (black bars) and nucleus (white bars) with the complexes prepared with pEGFP plasmid containing GFP reporter gene. The percentage of cytoplasmically injected cells that expressed GFP was calculated, as was the percentage of cells that were GFP positive following injection into the nucleus. The results are presented as a mean of three independent experiments and standard deviation.
oocytes microinjections, no significant changes in gene expression resulted from crosslinking the complexes. Cytoplasmic microinjections resulted in almost 15% of injected cells expressing reporter GFP irrespective of the type of complex used, while direct intranuclear injection led to about 70% of expressing cells with all four formulations.
We have also tested the possibility that the results may be caused by the presence of free DNA. The TEM pictures, however, did not show any evidence of free DNA in the crosslinked complexes, and agarose gel electrophoresis showed no detectable free DNA. Therefore the amount of possibly contaminating free DNA in the mixture must be very low. It is known that the signal obtained following microinjection of free DNA into cells is heavily dose-dependent 9 (Carlisle, unpublished results), while the expression achieved here using crosslinked complexes is very similar to that obtained using equivalent concentrations of free DNA. Hence the results cannot be accounted for by traces of free DNA.
The microinjection experiments demonstrated that the crosslinked complexes are capable of efficient transgene expression following arrival in the cytoplasm or nucleus. Together with the cellular uptake data and the transfection study, this suggested that crosslinking might affect their efficiency of transfer from the endosome into the cytoplasm. Transfection experiments used for 'screening' of the crosslinked complexes were performed in the presence of chloroquine, which is thought to facilitate endosomal escape of the complexes (Figure 7 ). Under these conditions the DTBP crosslinking led to major decreases in transgene expression. However, experiments performed in both the presence and absence of chloroquine showed chloroquine has a much greater ability to potentiate transfection activity of non-crosslinked complexes than crosslinked complexes, particularly using PEG-coated complexes. Indeed, comparison of complexes in the absence of chloroquine showed less inhibition by crosslinking ( Figure 10) . Hence it is possible that the loss of transfection activity following crosslinking reflects failure of chloroquine to potentiate endosome-to-cytoplasm transfer ( Figure 7) .
The profile of gene expression over time, in the absence of chloroquine, is also different using crosslinked and non-crosslinked complexes: after 24 h the transfection activity of PEG-DTBP(10) complexes was about 50% that of non-crosslinked complexes, whereas by 48 h the differential was much less. This suggests that maximum gene expression was somewhat delayed by the crosslinking, perhaps reflecting time-dependent reduction of the complexes inside the cell. The transgene expression data obtained in the absence of chloroquine in a way confirmed the results of both microinjection experiments. They have both shown that even the highly crosslinked complexes are transfection competent, and that poor endosomal escape could be the reason for the low transgene efficiency.
Discussion
For effective systemic delivery of therapeutic genes, a new generation of 'smart' vectors must be developed that are likely to adapt key functions from viruses. Apart from other properties these vectors should be stable and inactive when in transit to their target cells, but should undergo rapid triggered activation following cell entry, enabling release and transport of the therapeutic gene to the nucleus.
We have recently developed a multivalent hydrophilic polymer to provide polycation/DNA complexes with a surface protective layer and at the same time increase their lateral stability by surface-crosslinking. 2 The polymer used in that study was designed to be cleaved, and the complex activated, intracellularly by lysosomal cathepsin-mediated proteolysis; however levels of transgene expression achieved suggest inefficient activation, perhaps because the route of productive transfection may not be via the lysosome. 10 To further improve this approach, here we have developed an alternative strategy that allows activation of the vector within the cytosol, rather than the lysosome. We have introduced lateral stabilization by crosslinking of preformed complexes with low-molecular weight crosslinker DTBP and then improved the colloidal stability of the complexes by surface coating with PEG. Use of low molecular weight crosslinking agent and incorporation of a PEG coating in this way permits us to control the stealth layer on the surface of complexes and the lateral stabilization independently.
Crosslinking of preformed PLL/DNA complexes with DTBP offers a simple method of stabilization, with crosslinks thought to form predominantly on the surface of the complexes. This is different from approaches using thiol containing DNA-condensing agents where the whole volume of the complex is likely to be crosslinked, making it more difficult to activate the crosslinked complexes within the cell. It is also beneficial to use imidoester crosslinkers as they react with amino groups while preserving positive charge. This appeared to be an important characteristic in keeping size of the complexes unchanged during the crosslinking reaction.
Crosslinked complexes could be surface-coated with PEG to provide increased colloidal stability and solubility characteristics. Hence the combination of crosslinking with DTBP and surface coating with PEG led to increased stability against polyelectrolyte exchange reactions (both with polyanions and polycations) and prevented both aggregation and dissociation in the presence of NaCl.
Interestingly, PEG-coating of non-crosslinked complexes showed that although coating could protect particles from aggregation it does not effectively block the access of smaller molecules (like PAA or PLL) to the complexes, determined by their susceptibility to exchange reactions. Moreover, it appears that coating with PEG even destabilizes the complexes to challenge by other polyelectrolytes. We assume this is a consequence of a partial disruption of hydrophobic interactions within the complex, which, apart from dominating Coulombic interactions, are playing an important role in additional stabilization of the polyelectrolyte complexes.
We hypothesized that the low resistance of PEG-coated complexes to polyelectrolyte exchange reactions is one of the major reasons for the fast removal of coated complexes from the bloodstream. 7 Following i.v. administration, normal polyplexes are exposed to a variety of factors that may compromise their integrity, including interaction with the charged proteoglycan-containing extracellular matrix, 11 with negatively charged cell membranes (notably erythrocytes), or with high concentrations of proteins and other molecules in blood plasma. We consider that these interactions, together with the shear stress in the blood circulation, could lead to exchange reactions both of DNA and polycation and result in at least partial decomplexation. In the case of polymer-coated complexes this may result in loss of the protecting polymer layer on the surface of the complexes. 7 We therefore anticipated that the stabilization of the complexes by crosslinking might lead to increased circulation times after i.v. administration. Significantly extended distribution kinetics of the crosslinked complexes confirmed this hypothesis (Figure 6 ), particularly since the extended circulation correlated with the degree of crosslinking, ie increased stability against exchange reactions. Extended blood circulation of crosslinked complexes correlated with less accumulation in the liver, suggesting that capture of the complexes by RES was decreased.
We expected that the increased resistance against exchange reactions might significantly diminish transgene expression from crosslinked complexes, as some reports have already shown that dissociation of DNA from the complexes is a necessary prerequisite for high transgene expression. 4, [12] [13] [14] For example, Schaffer et al 12 showed that the increase in complex stability correlated inversely with the gene transfer efficiency when studied using PLL of different molecular weights. The transfection data obtained here in the presence of chloroquine ( Figure 7 ) suggested that the crosslinked complexes did lose their activity, the most likely explanation being that the intracellular reducing potential is not sufficient to activate the complexes. However, microinjection studies showed that when microinjected directly into cytoplasm or nucleus of Xenopus oocytes and Rat-1 cells the crosslinked complexes are competent for transgene expression at levels that are at least equal to those provided by non-crosslinked complexes. This suggested that
Gene Therapy the disulfide bridges, capable of endowing good stability to the complex extracellularly, are efficiently reduced within the cytoplasm or nucleus, enabling transcription of DNA contained in the vector. The observation of good transgene expression activity from crosslinked complexes reaching the cytoplasm or nucleus, coupled with no change in the level of cellular uptake, suggested that the reason for poor transfection activity might lie in differential endosome-to-cytoplasm transfer of crosslinked and non-crosslinked complexes. In particular, chloroquine appeared to have selective potentiating activity since transfection studies in the absence of chloroquine showed similar levels of gene expression of both crosslinked and non-crosslinked complexes. In fact, there is evidence that partial dissociation of polyelectrolyte complexes may play a role in chloroquine-mediated endosomal escape of DNA, with high endosomal levels of chloroquine (estimated as 20 mm 4 ) binding DNA and destabilizing the complex. It could be proposed that the resulting partially freed polycation might bind to the endosome membrane and contribute to increased transfer. We therefore hypothesize that the dissociation component of chloroquine action is most affected by the crosslinking. This assumption is further supported by our observation of increased stability of the crosslinked complexes against chloroquine-induced aggregation (Table 2) .
Interestingly, several other groups have very recently described the use of disulfide-based trigger strategies for gene delivery. All the approaches led to improvements of certain aspects of stability of polyelectrolyte complexes but none has shown any improvements in systemic biodistribution of the complexes of the sort demonstrated here. 15, 16 Oxidation of DNA complexes containing short synthetic peptides bearing multiple cysteine residues prevented dissociation of the complexes and their transfection efficiency was inhibited by increasing the number of cysteine residues in the peptide used. 16, 17 Another study recently described the use of DTBP to crosslink polycation/DNA complexes. The authors, however, concluded that the crosslinked complexes lost their transfection activity and proposed therefore that it was necessary to use less stable disulfide linkage; notably the study included no microinjection component, so intracytoplasmic reduction could not be assessed directly. 6 In summary, this study shows that the apparently contradictory demands for successful systemic administration and efficient gene expression of nonviral gene delivery vectors can be addressed by design of complexes for activation by appropriate trigger mechanisms. Application of reduction-cleavable surface crosslinking provides extracellular stability, with extended plasma circulation times, coupled with efficient transgene expression following entry into target cells. Such systems provide a realistic new paradigm for targeted delivery of genes.
Materials and methods
Materials A circular 5.2 kb plasmid vector pGL3-con (Promega UK, Southampton, UK) containing the SV40 promoter-driven luciferase reporter and ampicillin resistance genes was used throughout except for microinjection studies in Rat-1 fibroblasts where a circular 4.7 kb vector pEGFP (Clontech, Basingstoke, UK) containing CMV promoterdriven GFP reporter and ampicillin resistance genes was used. Poly-l-lysine hydrobromide (PLL) (19.6 kDa), FITC-PLL (19.6 kDa), and poly-l-aspartic acid (36.9 kDa) were from Sigma (Poole, UK). Dimethyl-3,3′-dithiobispropionimidate (DTBP), and 3,3′-dithiobis(sulfosuccinimidyl propionate) (DTSSP) were from Pierce & Warriner (Chester, UK). O-[2-(NSuccinimidyloxycarbonyl)-ethyl]-O′-methylpolyethylene glycol (5 kDa) (PEG-NHS) was obtained from Fluka (Dorset, UK). Unless otherwise mentioned, all other reagents were obtained from Sigma.
Formulation of complexes
Polycation/DNA complexes were routinely prepared at N/P ratio (ratio of PLL amino groups to DNA phosphates) of 2 by adding water stock solution of 2.5 mg/ml PLL to DNA solution (20 g/ml in 10 mm Hepes pH 7.4). To crosslink individual complexes, different amounts of crosslinker dissolved in water were added, followed by addition of 0.5 m Hepes pH 7.8 to a final concentration 40 mm. The complexes are designated according to the degree of crosslinking; ie DTBP(10) indicates PLL/DNA complex crosslinked with DTBP using a molar ratio of 10 between DTBP and total amino groups of PLL, similarly DTBP(0) describes non-crosslinked PLL/DNA complexes. After 3 h of crosslinking reaction PEG-NHS (40 mg/ml in water) was added (final concentration 3 mg/ml; unless otherwise stated) and left overnight to produce coated complexes.
PEG-coated complexes were concentrated and purified using Viva Spin 20 concentrators (MW cut-off 100 kDa) (VivaScience Ltd, Binbrook, UK). The concentrators were first washed with 10 ml of miliQ-water and then 15-20 ml of sample was centrifuged at 900 g until the desired final volume was reached. Concentrations of DNA up to 1 mg/ml were routinely achieved with recovery over 90% and without significant increase in the size of the complexes.
Determination of the extent of coating reaction
The percentage of amino groups of PLL reacted with PEG-NHS in the coating reaction was determined by TNBSA assay. 18 Briefly, 0.4 ml of 0.1 M Na 2 B 4 O 7 was mixed with 0.4 ml of complexes and 20 l of TNBSA solution (0.03 M in water). Absorbance at 420 nm was measured after 30 min incubation at 20°C.
Measurement of size and potential
The hydrodynamic diameters of the complexes were measured by dynamic light scattering (DLS) using a ZET-ASIZER 1000 (Malvern Instruments, Malvern, UK) equipped with a 70 mW external argon laser. The measurements were performed in triplicate at 25°C in Hepes buffer (40 mm, pH 7.8) at the scattering angle 90°a nd analyzed by CONTIN. The potentials of the complexes were measured using ZETAMASTER equipped with a 5 mW internal neon laser. Sampling time was set to automatic, and the range was set to unknown. All potentials were determined in 40 mm Hepes buffer pH 7.8. The apparatus was calibrated with −50 mV standards before experimental measurements.
Determination of the morphology of PLL/DNA complexes using transmission electron microscopy DTBP(0), DTBP(10), PEG-DTBP(0) and PEG-DTBP(10) were prepared as described above. Then, 5 l of each solution was dispensed on to 200 mesh carbon coated copper grids (glow discharged before use) and left for 1 h at room temperature. The remaining solution was drawn off using filter paper and the mesh washed in deionised water and left to dry overnight at room temperature. Uranyl acetate (10 l of 2% freshly filtered solution) was added for 2 min, removed by filter paper, the mesh washed by immersion in deionised water and left to dry. The samples were then viewed using a Joel 1200 EX Transmission Electron Microscope under 50 000 magnification.
Dissociation of the complexes by NaCl
The effect of crosslinking on the stability of the complexes against dissociation by NaCl was studied using a Perkin Elmer (Buckinghamshire, UK) LS50B fluorimeter with exc = em = 600 nm. The assay was based on a significant reduction of scattering signal from dissociating complexes. Typically, aliquots of 5 m NaCl were added to 2 ml of complexes in Hepes pH 7.8 and changes in the intensity of scattered light were followed.
Dissociation of the complexes by poly-L-aspartic acid
The stability of complexes against exchange reaction with poly-l-aspartic acid (PAA) was evaluated by restoration of ethidium bromide/DNA fluorescence and by agarose gel electrophoresis, where release of free DNA was observed.
Stability of complexes was examined by measuring the ability of PAA to restore fluorescence of ethidium bromide/DNA. Ethidium bromide was added (final concentration 2.4 g/ml) to the solution of complexes and changes in the fluorescence caused by subsequent addition of aliquots of PAA were measured ( exc = 510, em = 590, slit width 5 nm, emission cut-off filter 515 nm). For the agarose gel electrophoresis assay, 20 l of complexes was incubated with 5 l of PAA (5 mg/ml) at 37°C for 30 min. The samples were then loaded on to a 0.8% agarose gel containing 0.5% ethidium bromide and run for 60 min at 110 V in 0.5× TBE buffer. To test reducibility of the crosslinking in some experiments 20 l of complexes was first incubated in 25 mm DTT, then PAA was added and samples were analyzed on agarose gel.
Polylysine and chloroquine-induced aggregation of complexes The ability of PLL (19.6 kDa) to cause aggregation of complexes coated with PEG was monitored using DLS. To 0.6 ml of coated complexes (prepared 24 h before the experiment) in 0.15 m NaCl (added 30 min before) 30 l of 2.5 mg/ml of PLL was added to the solution and changes in size of the complexes were monitored. Similarly, the ability of chloroquine to cause aggregation of both coated and non-coated complexes was assessed by measuring changes in the complex sizes by DLS.
Transfection procedures in vitro
The murine mouse melanoma cell line B16F10 was grown in DMEM/Glutamax (Gibco BRL, Paisley, UK) and 10% heat inactivated fetal calf serum (FCS). For all transfections experiments 8000 cells per well were seeded in 48-well plates (Gibco BRL, UK) in 0.5 ml DMEM containing 10% FCS. Transfections were performed after 1 day in DMEM (150 l per well) with or without 100 m chloroquine and in the presence of 10% FCS. Transfections were carried out in triplicates with 25 l complexes containing 500 ng DNA per well. After a 4 h incubation at 37°C, the medium was replaced with 0.5 ml of fresh DMEM containing 10% FCS. After 24 h, cells were washed with Dulbecco's phosphate-buffered saline (Gibco BRL, UK) and harvested in 100 l of Promega cell lysis solution (Promega, UK). Luciferase activity was measured from an aliquot of the lysate using a Lumat LB9507 (Berthold) after automatic injection of 100 l assay buffer containing D-luciferin for 10 s. Protein concentrations in cell lysate were measured by Bicinchoninic acid (BCA) assay (Sigma) using bovine serum albumin as a standard. The amount of luciferase in each sample was normalized to milligram of protein and reported as the mean and standard deviation obtained from triplicate transfections. One ng of recombinant luciferase (Promega) corresponds to 6 × 10 7 relative light units (RLU).
Radiolabeling of DNA expression vectors
Plasmid DNA was linearized with HindIII and then radiolabeled with 32 P-dCTP using the Ready-to-Go Oligolabeling kit (Pharmacia Biotech, St Albans, UK). Unincorporated nucleotides were removed using MicroSpin columns (Pharmacia Biotech) and the purity of the labeled DNA checked following agarose gel electrophoresis and quantitative analysis with a PhosphoImager (Molecular Dynamics, Chesham, UK).
Cellular uptake in vitro
For uptake measurements 8000 B16F10 cells per well were plated into a 48-well plate 24 h before experiment in DMEM with 10% FCS. Complexes were prepared as described above, except DNA was trace-labeled by the addition of a small amount of 32 P-DNA before the addition of polycation. Cells were incubated for 4 h with 25 l complexes plus 0.15 ml of DMEM containing 100 m chloroquine and 10% FCS. The incubation was performed at 37 and 4°C. In order to stabilize the pH in the absence of a controlled CO 2 environment, internalization studies were performed in the indicated medium containing 20 mm Hepes pH 7.4. After 4 h incubation the cells were washed twice with PBS and lysed with 0.5 ml of Promega lysis buffer. The amount of radioactivity associated with cells was measured in a Packard Scintillation counter. The uptake is represented as a percentage of the total after correction for cell binding determined at 4°C. The results are presented as a mean and standard deviation obtained from three samples.
Microinjection into Xenopus oocytes
Frogs were lightly anesthetized and killed by rapid destruction of the brain, ovaries removed and dissected in modified Barth's saline (MBS -88 mm NaCl, 1 mm KCl, 2.4 mm NaHCO 3 , 15 mm Hepes pH 7.6, 0.3 mm Ca(NO 3 ) 2 , 0.41 mm CaCl 2 , 0.82 mm MgSO 4 , 50 g/ml Gentamycin). Washed intact oocytes were transferred into fresh MBS and left overnight at 20°C. The oocytes were examined the next day under the microscope and the healthy looking ones at developmental stage IV were transferred to a new dish containing MBS.
The oocytes were injected with pGL3-control plasmid
Gene Therapy containing complexes within 48 h after isolation using a glass capillary. After injection the oocytes were left at 20°C. Forty-eight hours later they were assessed for luciferase gene expression as described above. Gene expression is reported as the mean RLU per five oocytes (randomly chosen) and standard deviation obtained from at least 12 groups of five oocytes.
Microinjection into Rat-1 fibroblasts Microinjection studies were conducted using an Eppendorf transjector 5246, an Eppendorf micromanipulator 5171 and an inverted fluorescence microscope (Zeiss Axiovert 100). The Rat-1 cell line was chosen due to its well defined nucleus and large cytoplasm. The pEGFP plasmid was used for expression studies.
Rat-1 cells were plated on to glass Cellocate grids (BDH/Merck, Lutterworth, UK) and grown in DMEM with 10% FCS for 24 h at 37°C. The grids were then washed with PBS and transferred into DMEM containing 20 mm Hepes but no FCS. Complexes were formed at an N/P ratio of 2 at a final DNA concentration of 20 g/ml as described above. To enable assessment of injection success 2 l of 50 mg/ml 200 000 kDa TRITC-dextran (Sigma) was added to 50 l of each sample. Before injection the samples were centrifuged at 10 000 r.p.m. for 5 min. Samples were back-loaded into Femptotip microinjection needles (BDH/Merck) and cells injected using an injection pressure of 50 p.s.i., a back-pressure of 100 p.s.i. and an injection duration of 0.5 s. Half of the grid was dedicated to injections into the cytoplasm and the other half was dedicated to injections into the nucleus; the same needle was used for both cytoplasmic and nuclear injections. Observation using filter setting suitable for TRITC allowed evaluation and recording of the number of successful injections performed. The glass grid was then washed with PBS and transferred back into DMEM containing 10% FCS, and incubated at 37°C. After 24 h the number of GFP-positive cells was counted using a setting for FITC (490/520 nm). The percentage of cytoplasmically injected cells that expressed GFP was calculated, as was the percentage of cells that were GFP positive following injection into the nucleus. The microinjections were performed on three separate occasions always with fresh preparations of the complexes.
In vivo biodistribution study Plasmid DNA (pGL3-control) was spiked with 32 P-labeled DNA and the complexes were formed, crosslinked, and coated with PEG-NHS 24 h before the experiment as described above. The complexes were concentrated to DNA concentration of 0.8-1 mg/ml 4 h before injection.
Immediately before injection, 50% glucose was added to a final concentration of 5% (w/v) to ensure iso-osmolarity. Complexes (100 l, containing 80-100 g of DNA per mouse) were administered via the tail vein to briefly anesthetized female BALB/c mice (22-25 g). After 30 min the animals were killed and dissected to permit determination of the radioactivity distribution. Blood samples were taken and the lung, liver, spleen, kidneys, intestines, and carcass were isolated, weighed and dissolved separately in 10 m sodium hydroxide at 80°C. Scintillation medium Ultima-Flo (20 ml) was added to each blood (50 l) or tissue (1 ml) sample before geometry-corrected analysis of their contained radioactivity in a Packard scin-tillation counter. A bloodstream volume of 8.64 ml/100 g body weight was assumed. 19 To separate red blood cells, the blood samples were centrifuged at 5000 r.p.m. for 1 min. The distribution of radioactivity between blood plasma and cellular fraction was then determined as described above.
The amount of radioactivity in each tissue is reported as the mean and standard deviation of the total recovered dose obtained in triplicate injections.
